ArticleNature2019
Publisher Correction: Harnessing innate immunity in cancer therapy.
Article in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Microbial manipulators:Journal of oral microbiology · 2025Review
- Exosomes, their sources, and possible uses in cancer therapy in the era of personalized medicine.Journal of cancer research and clinical oncology · 2024Review
- Review
- Targeting Innate Immunity in Glioma Therapy.International journal of molecular sciences · 2024Review
- Risk for cancer development in familial Mediterranean fever and associated predisposing factors: an ambidirectional cohort study from the international AIDA Network registries.Frontiers in immunology · 2024Article
- Immunotherapeutic Agents for Intratumoral Immunotherapy.Vaccines · 2023Review
- Anthocyanins as Immunomodulatory Dietary Supplements: A Nutraceutical Perspective and Micro-/Nano-Strategies for Enhanced Bioavailability.Nutrients · 2023Review
- Abnormal genetic and epigenetic patterns of m6A regulators associated with tumor microenvironment in colorectal cancer.Translational cancer research · 2023Article
- LPS combined with CD47mAb enhances the anti‑osteosarcoma ability of macrophages.Oncology letters · 2023Article
- DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma.Cancer letters · 2022Article
- Inflammation-related pyroptosis, a novel programmed cell death pathway, and its crosstalk with immune therapy in cancer treatment.Theranostics · 2021Review
Corrections and comments
- Erratum for
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An Amendment to this paper has been published and can be accessed via a link at the top of the paper.
Identifiers
31745371What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.